Impella在儿科患者中的多机构应用结局:ACTION网络简报
主要诊断为扩张型心肌病(57.3%),28%发生大出血、大感染、装置故障或卒中,89.3%获得阳性临床结局。数据显示该装置在儿童难治性晚期心衰中可能具有作用,并需努力减少不良事件。
要点
- Impella在儿科难治性晚期心衰中89.3%获阳性结局。
- 28%患者发生大出血、大感染、装置故障或卒中。
- 57.3%为扩张型心肌病,14.7%为移植移植物功能障碍。
核心结论
- Impella在儿童难治性晚期心衰中可能具有作用,但需增加工作以减少不良事件。
主要发现
- 中位体重62.9 kg(IQR 51.0-79.7 kg),最小体重19.0 kg。
- 腋动脉植入占40.1%,股动脉占29%。
- 扩张型心肌病占57.3%,移植移植物功能障碍占14.7%,先天性心脏病占13.3%。
- 28%(N=42)报告大出血、大感染、装置故障或卒中;89.3%获得阳性临床结局,其中32.7%因恢复拔除、32%移植、23.3%更换为其他装置。
临床怎么用
- 对于儿科难治性晚期心衰患者,Impella可作为机械循环支持的一种选择。
- 使用Impella时需警惕大出血、大感染、装置故障和卒中等不良事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This retrospective cohort study includes 150 pediatric patients supported with the Impella between April 2018 and November 2024. Median weight was 62.9 kg (interquartile range [IQR] 51.0-79.7 kg) and the smallest weighed 19.0 kg. Axillary artery implants occurred in 40.1% of patients while the femoral artery was used in 29%. Most patients had dilated cardiomyopathy (57.3%); however, a significant portion had transplant graft dysfunction (14.7%) or congenital heart disease (13.3%). One quarter of the cohort (N = 38) were supported with extracorporeal membrane oxygenation (ECMO) before Impella; 76% (N = 29) used ECMO and Impella in tandem, while 24% (N = 9) transitioned from ECMO to Impella. Major bleeding, major infection, device malfunction, or stroke were reported in 28% of patients (N = 42). Positive clinical outcomes were achieved in 89.3% of patients; 32.7% explanted for recovery, 32% transplanted, and 23.3% changed to another device. These data demonstrate a potential role for this device in children with refractory advanced heart failure and a need for increased work to limit adverse events.
引用
- Edelson JB, Amdani S, Rosenthal DN, et al. Multi-institutional outcomes of Impella use in pediatric patients: A brief communication from the ACTION Network. J Heart Lung Transplant. 2025. PMID: 40505789. doi:10.1016/j.healun.2025.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。